.B{stroke:#000}.C{stroke-miterlimit:8}.D{fill:none}.E{fill-rule:evenodd}.F{stroke-width:10.667}.G{stroke-width:6.667}

About the Baker Institue Lipidomics PheWeb

Our discovery cohort consists of 4,492 individuals from the Busselton Health Study. Two independent cohorts - the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) study and the Alzheimer's Disease Neuroimaging Initiative (ADNI) study - provide validation of SNP-lipid associations.

For detailed information about the analysis and cohorts, please see our preprint: Cadby, G. et al. Comprehensive genetic analysis of the human lipidome identifies novel loci controlling lipid homeostasis with links to coronary artery disease (2021).

Cohort Description
Baker Heart and Diabetes Institute

About the Baker Institue Lipidomics Platform

The Baker Heart and Diabetes Institute Metabolomics Laboratory has developed a state-of-the-art lipidomics platform, emphasizing precise and reliable measurement of a broad range of lipid species from human plasma. This website describes the targeted LC-MS/MS method for the determination of 761 different human lipid species using just 10 µL of plasma. The total analysis time is 16 minutes per sample using a single column, reduced to 13 minutes when running a dual column system.

Our platform has been built from the ground up to separate isomers and isobaric species, allowing an unparalleled specificity in lipid measurement. We have developed a freely available online resource detailing our lipidomic methodologies. This resoure will allow the research community to replicate our lipidomic platform.

Submit enquiries and view contact information on our Contact Us page.

If you have questions about our laboratory or projects, email Peter.Meikle@baker.edu.au. If you have questions about this website, email Corey.Giles@baker.edu.au.